TTH Share Price

Open 1.94 Change Price %
High 1.95 1 Day 0.00 0.00
Low 1.93 1 Week 0.00 0.00
Close 1.93 1 Month 0.00 0.00
Volume 7200 1 Year -0.48 -19.92
52 Week High 2.85
52 Week Low 0.89
TTH Important Levels
Resistance 2 1.95
Resistance 1 1.94
Pivot 1.94
Support 1 1.92
Support 2 1.91
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 4.03 3.60%
ECA 16.85 -0.82%
ECA 16.85 -0.82%
ECA 16.85 -0.82%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
ANX 0.06 20.00%
ANX 0.06 20.00%
MBA 0.58 13.73%
MBA 0.58 13.73%
More..
TSE Canada Top Losers Stocks
ST 0.02 -33.33%
ST 0.02 -33.33%
GBV 0.46 -24.59%
RN 0.10 -16.67%
RN 0.10 -16.67%
IMP 0.06 -14.29%
IMP 0.06 -14.29%
IMP 0.06 -14.29%
KOR 0.61 -11.59%
KOR 0.61 -11.59%
More..

Transition Therapeutics Inc (TSE: TTH)

TTH Technical Analysis 4
As on 29th Aug 2016 TTH Share Price closed @ 1.93 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.88 & Strong Buy for SHORT-TERM with Stoploss of 1.69 we also expect STOCK to react on Following IMPORTANT LEVELS.
TTH Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TTH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transitiontherapeutics.com
TTH Address
TTH
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada
Phone: 416-260-7770
Interactive Technical Analysis Chart Transition Therapeutics Inc ( TTH TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transition Therapeutics Inc
TTH Business Profile
Transition Therapeutics Inc., a biopharmaceutical company, develops therapeutics for various disease indications primarily in Canada. Its lead CNS drug candidate includes ELND005, a Phase II clinical trial product for the treatment of Alzheimer's disease, bipolar disorder, and down syndrome; and lead metabolic drug candidate comprises TT-401 for the treatment of type 2 diabetes and accompanying obesity. The company’s product pipeline also consists of TT-402 to treat diabetes; and TT-601, a preclinical stage product for the treatment of osteoarthritis pain. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005; and Eli Lilly and Company. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. on December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.